DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer
February 06 2020 - 4:01PM
Montrouge, France, February 6, 2020
DBV Technologies Announces Appointment of
Pascal Wotling as Chief Technical Operations Officer
DBV Technologies (Euronext: DBV - ISIN:
FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced the appointment of
Pascal Wotling as its Chief Technical Operations Officer (CTOO),
effective April 1, 2020. Pascal will be responsible for
manufacturing, supply chain and new product process development,
and will serve as a member of the Executive Committee, reporting to
Daniel Tassé, Chief Executive Officer of DBV Technologies.
“I am delighted to have Pascal on the team –
he’s a committed leader bringing two decades of expertise managing
complex drug manufacturing operations,” said Daniel
Tassé. “His experience will be crucial as he drives the
execution of our manufacturing strategy, including new product
development, to progress our organization to commercialization and
help bring our first product to patients, if approved.”
Pascal will be based in Bagneux, France, and
oversee manufacturing, supply chain and new product process
development. He brings more than two decades of technical
operations experience, specializing in the pharmaceutical industry.
He most recently served as Head of External Supply Operations,
Asia-Pacific, Middle East and Africa in Shanghai for Novartis.
Pascal spent 17 years at Novartis Technical Operations, where he
led businesses and teams in engineering, manufacturing, site
leadership and external supply operations. Earlier in his career,
he served as head of Engineering and Health, Safety and Environment
in an Amcor Plc. factory.
“The potential of the unique Viaskin technology
platform is incredible, and I’m grateful for the opportunity to be
a part of the team that could possibly offer innovative treatment
options to patients, if approved,” said Pascal
Wotling. “This is an important time not just for DBV, but
for children and families struggling with the burden of food
allergies, who ultimately need treatment options that could fit
into their daily lives.”
About DBV Technologies DBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPITTM, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut and Viaskin Milk, and preclinical development of Viaskin
Egg. DBV is also pursuing a human proof-of-concept clinical study
of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and
exploring potential applications of its platform in vaccines and
other immune diseases. DBV Technologies has global headquarters in
Montrouge, France and offices in Bagneux, France, and North
American operations in Summit, NJ and New York, NY. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing one-half of one ordinary share)
are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding the potential of the EPIT platform.
These forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this
stage, the products of the Company have not been authorized for
sale in any country. Among the factors that could cause actual
results to differ materially from those described or projected
herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and
approvals and the risk that historical clinical results in one
patient population may not be predictive of future clinical trial
results in different patient populations. A further list and
description of these risks, uncertainties and other risks can be
found in the Company’s regulatory filings with the French Autorité
des Marchés Financiers, the Company’s Securities and Exchange
Commission filings and reports, including in the Company’s Annual
Report on Form 20-F for the year ended December 31, 2018 and future
filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
DBV Investor Relations Contact
Sara Blum ShermanSenior Director, Investor Relations &
Strategy+1 212-271-0740sara.sherman@dbv-technologies.com
DBV Media Contact Joe BeckerVP,
Global Corporate Communications
+1 646-650-3912joseph.becker@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Sep 2024 to Oct 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Oct 2023 to Oct 2024